Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Advances in Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted protein degradation: expanding the toolbox

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Bivalent Ligands for Protein Degradation in Drug Discovery

The Present and Future of Novel Protein Degradation Technology

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

Recent advances in targeted protein degraders as potential therapeutic agents

Precise Modulation of Protein Degradation by Smart PROTACs

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs